BUCHAREST – June 21, 2024 – The American Society of Clinical Oncology (ASCO) 2025 Congress is a crucial event, presenting forefront achievements in cancer research and therapeutics. Leading experts shared significant progress during the conference focused on diagnostics and drugs. In this report we summarise some key findings.
The yearly ASCO congress, brings together international researchers to highlight critical advances in treating several cancers, discussing everything from innovative treatments to new clinical trials. Featuring presentations of groundbreaking studies and cutting-edge therapies,including advancements in treatments for lung,breast and gynecological cancers,ASCO continues its role to lead efforts in developing improved outcomes for patients.
The Annual Congress of the American Society of Clinical Oncology (disgust) 2025 is presented as one of the most relevant events worldwide in the field of oncology. Gathering international researchers, clinicians and experts, disgust 2025 serves as a key forum to present the Last advances In research, innovative treatments and strategies aimed at improving the care of cancer patients, promoting global collaboration in the fight against this disease.
Outstanding advances in oncological therapies
During Congress sessions Studies and therapies were announced that promise to transform the approach to various types of cancer with high mortality. Astrazeneca presented the results of the Serena-6 studythat with a sample of 10,000 patients Evaluate camizestrantan oral drug that by liquid biopsy detects mutations in the ESR1 gene to anticipate molecular progression and adjust the treatment before it is visible in image tests.
Also, the Matterhorn essaywith 43,000 patients with Gastric cancer in intermediate stagesshowed that adding immunotherapy with Durvalumab together with standard chemotherapy before surgery increased progression -free survival to 67% to two years and reduced the risk of relapse by 29%, with controllable toxicity.
Innovation in small cell lung cancer
Pharmamar presented the results of the study of fase III IMfortewhich evaluates the Zepzelca combination (lurbinectedina) with atezolizumab As first -line maintenance therapy for patients with advanced small cell lung cancer after induction treatment.
The essay met its primary goals, showing Significant improvements in free survival of global progression and survival Regarding Atezolizumab in monotherapy, positioning this combination as a new standard for maintenance treatment.
Numerous types of cancers
Bristol Myers Squibb stood out with more than 80 studies presented, including a phase III trial in plenary session that Evaluate Nivolumab combined with radioquimiotrapy as a adjuvant treatment in exhaustable head and neck carcinoma with high risk of relapse.
In addition, they shared five -year survival data from Studies like Checkmate-816, Checkmate-77T and Checkmate-577which cover non -microcytic lung cancer, esophagus and esophagogastric union. In the field of research, they advanced in IPRMT5 nests, combinations of adagrasib and pembrolizumab For KRASG12C mutations, and Bio -specific antibodies aimed at non -classic EGFR mutations in lung cancer.
Findings in multiple myeloma and other tumors
Johnson & Johnson presented a wide portfolio with more than 70 summaries and 13 oral presentations centered on multiple myeloma, B and myeloid neoplasms, as well as solid tumors such as lung, prostate and colorectal cancer.
Among its main findings highlighted the data to five years of the CARTIVITY-1 study With Carvykti (cylta-cel) in recurrent/refractory multiple myeloma, as well as results of the CARTIVITY-4 AND CEPHEUS STUDIES They evaluate daratumumab in different combinations for patients with newly diagnosed myeloma. New data on Ibruvica (Ibrutinib) also presented in chronic lymphocytic leukemia and mantle cell lymphoma, and advances in prostate cancer treatments with AKEEGA and JNJ-78278343, a new T-cell activator.
In lung cancer, results of the Cocoon study to reduce cutaneous side effects and butterfly-2 study in patients with progression after Osimertinib. In colorectal cancer, they showed Preliminary amivantamab data In refractory metastatic patients.
New evidence in oncological therapies
Astellas Pharma presented 16 summaries focused on bedological therapies approved, making special emphasis on global survival updates which confirm its clinical value.
Among the novelties are the five -year global survival analysis of the ARCHES STUDYwhich evaluates enzalutamide (xtandi) combined with androgen deprivation therapy in metastatic prostate cancer sensitive to hormones, as well as data to eight years of the eight years of the ENZAMET STUDY.
They also presented analysis of the PHASE 3 EV-302 STUDYwhich evaluates Enfortumab Vedotin (Padcev) together with Pmbrolizumab against advanced urothelial carcinomarapy, and a systematic review of substitute criteria in bladder cancer tests with muscle invasion.
Research in solid and hematological tumors
Gilead Sciences and his Kite subsidiary presented more than 20 summaries that cover a wide variety of solid and hematological tumors, including breast cancer, glioblastoma, endometrium cancer, lung, gastric, multiple myeloma and lymphomas.
They highlighted updated data from PHASE 3 ASCENT-04 STUDYwhich demonstrated a significant benefit in free survival in advanced triple negative breast cancer when combining Trodelvy con Keytrudacompared to Keytruda more standard chemotherapy.
In addition, Kite presented promising results of a phase 1 study that evaluates an innovative therapy with double target car-t cells In patients with recurring glioblastoma, in an outstanding oral session during Congress.
Gynecological tumors
Similarly, GSK announced the presentation of more than 60 new data on its oncological portfolio in disgust2025. These advances reflect the company’s commitment to improve the treatment of various types of cancer, including hematological, gynecological and other solid tumorsthrough innovative therapies.
Especially the results related to Mafodotin Belantamab For recurrent or refractory multiple myeloma. He Dreamm-8 study Evidence that the negativity of measurable residual disease is linked to better efficiency results. In addition, the security and efficacy data of the Dreamm-20 studywhich evaluates a new unconclosed monoclonal antibody, an important advance towards new generation therapies aimed at BCMA.
In the field of gynecological cancer, GSK advances in Understand the experience of patients to optimize both research and clinical attention. Studies that evaluate the combination of Dostarlimab with chemotherapy and maintenance treatments in advanced ovary cancer, as well as analysis that explore the impact of the progression of the disease on the quality of life of the patients. An analysis is also included that compares the effect on the quality of life of treatment with do
